Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>=18 years.~* Histological or cytological documentation of non hematologic, malignant solid tumour.~* Have failed at least one previous therapeutic regimen.~* Measurable disease according to RECIST 1.1.~* Life expectancy \>= 12 weeks~* ECOG Performance Status of 0 or 1~* Written, signed and dated informed consent~* Able and willing to meet all protocol-required treatments, investigations and visits.~* Have adequate organ function~Exclusion Criteria:~* Clinically significant non-malignant disease.~* Active CNS metastases.~* Subjects with uncontrolled diabetes.~* History of clinically significant adverse drug reaction to heparin or other anti-coagulant agents~* History of immune-mediated thrombocytopaenia or other platelet abnormalities or other hereditary or acquired coagulopathies.~* Concomitant use of aspirin (\> 150 mg/day), NSAIDs (except COX-2 selective inhibitors), vitamin K antagonists (other than low-dose prophylactic use), heparin within two weeks prior to randomisation, or other anti-platelet drugs.~* History of severe allergic, anaphylactic or other significant adverse reaction to radiographic contrast media~* Known seropositivity to the human immunodeficiency virus (HIV)~* Women who are pregnant or breast-feeding.~* Women of child-bearing potential and male subjects who are partners of women of childbearing potential who are unable or unwilling to practice a highly effective means of contraception.~* Active substance abuse~* Subjects who have received an investigational agent within 28 days prior to Cycle 1 Day 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PG545 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).